All In Biotech

NDA 209080 · Italfarmaco SA

Tiglutik Kit

Riluzole · Oral · Benzothiazole

Orphan

Last checked: Nov 21, 2026Latest source record: Sep 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 5, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

97

20 Phase 3, 11 recruiting

FAERS reports

2,216

1,375 serious, 521 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TIGLUTIK KIT · RILUZOLE 50MG/10ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Riluzole" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death319
  • nausea155
  • diarrhoea138
  • drug ineffective100
  • disease progression96
  • amyotrophic lateral sclerosis92
  • fatigue92
  • dyspnoea89
  • asthenia82
  • dizziness79
  • muscular weakness71
  • abdominal discomfort68

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200515
20067
200710
20089
20096
201013
201111
201215
201327
201421
201535
201639
201798
2018134
2019207
2020264
2021194
2022179
2023310
2024239
2025209
2026168

Recalls

1 FDA enforcement reports for this application.

  • Oct 20, 2023 · Class II · Terminated

    Failed Viscosity Specifications: Out-of-specification test results for viscosity

Shortages

FDA's drug shortage list.

  • Current · updated Nov 2, 2026

    Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 248 on PubMed

Sponsor: Italfarmaco SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.